These medications, originally approved by the FDA for the treatment of Type 2 diabetes, have since been authorized for weight loss therapy and are now recommended by the American Diabetes Association as potential first-line options for both indications
We have not experienced significant long-term side effects with our patients
However, if taking Retatrutide close to bedtime causes any digestive discomfort, adjust the injection timing earlier in the day
Even if your GLP-1/GIP receptors are fully adapted, the glucagon receptor is new to your system
Body mass index (BMI) and waist circumference (WC) also decreased by 2.96 kg/m and 9.6 cm, respectively
GLP-1 receptor agonists have shown the ability to reduce neuroinflammation and oxidative stresswell-recognized contributors to Alzheimers diseaseand provide neurotrophic effects in animal models of Alzheimers, the authors write, while cautioning that this needs to be verified by further clinical trials